Approval · Notice of Compliance 26345 · 2021
VIZIMPRO: Notice of Compliance 26345
Issued July 29, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26345
- Date
- July 29, 2021
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIZIMPRO | Not yet assigned | — |
Medicinal ingredients
- DACOMITINIB MONOHYDRATE 15 MG per TAB
- DACOMITINIB MONOHYDRATE 30 MG per TAB
- DACOMITINIB MONOHYDRATE 45 MG per TAB